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Anukant Mital 
International pilot study of schizophrenia 
(IPSS): Agra centre, India 
!  Multicentre, WHO at 2 and 5 years 
!   76% followed at 2 years (n=1,202)  
!  Consistent finding at 2 and 5 years was that 
schizophrenia in developing countries has better 
outcome 
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Government of India multicentre study on 
course and outcome of schizophrenia 
!  Time spent in psychotic state 
–  15% or less: 62%; 75% or more: 4% 
!  Best pattern of course: 45%; worst course: 10% 
!  Impairment of occupational functioning 
–  nil: 40%; severe: 18% 
!  Social impairment 
–  nil: 34%; severe: 12 % 
!  Overall outcome 
–  favourable: 66%; intermediate: 30%; 
unfavourable: 4% 
Indian Council of Medical Research (ICMR) 
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Complete Remission as Outcome status in Schizophrenia   
‘Real World’ Comparison of First- and Second- Generation Antipsychotics in 
Regard to Length of Inpatient Hospitalization and Number of Re-
hospitalizations( 2008)  
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1994 & 2004 
4 
Antipsychotics 
Whether to treat schizophrenia with 
antipsychotic? Banglore Study 
!  OBJECTIVE: To compare  disability in schizophrenia patients 
receiving antipsychotics and  untreated    
!  Untreated: unchanged Mean disability scores   
!  Continued to receive and initiated APD: showed a significant 
decline  disability. 
!  The proportion of patients classified as 'disabled' declined 
significantly in the treated group (P < 0.01), but remained the 
same in the untreated group 
Thirthalli J, Venkatesh BK, Kishorekumar KV, Arunachala U, Venkatasubramanian G, Subbakrishna DK, 
Gangadhar BN.  
Prospective comparison of course of disability in antipsychotic-treated and untreated schizophrenia 
patients. 
 Acta Psychiatr Scand. 2009 Mar;119(3):209-17 
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Treatment effectiveness in 
Schizophrenia ( World Health report 2001, 
WHO) 
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Dixon LB, Lehman AF (1995). Family interventions for schizophrenia. Schizophrenia Bulletin, 21(4): 631–
643. 
Dixon LB et al. (1995). Conventional antipsychotic medications for schizophrenia. Schizophrenia Bulletin, 
21(4): 567–577. 
CATIE – Phase 3, Symptom 
response 
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What is the prescribing pattern 
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SGAs have become the first-line treatment for psychiatric disorders. 
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1994 & 2004 
‘Real World’ Comparison of First- and Second- Generation 
Antipsychotics in Regard to Length of Inpatient Hospitalization and 
Number of Re-hospitalizations( 2008)  
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150 DB,  N= 21 533,   
4  Drugs  amisulpride  clozapine, olanzapine   risperidone  
were better than FGA, with small to medium ES.: 
The other SGA  were not more efficacious than the 
FGA, even for negative symptoms. 
With the exception of aripiprazole and ziprasidone, 
SGA drugs induced more weight gain  
The CATIE and CUtLASS studies in schizophrenia: results 
and implications for clinicians. 
!  CATIE and CUtLASS suggest that SGAs do not live up to all the previous 
expectations.  
!  However, even if most of these advantages are debatable, the lower risk of 
Tardive dyskinesia and the better subjective effects should be strong enough 
reasons to favour these drugs.  
!  There is no single antipsychotic that is best for every schizophrenia patient, 
as individual responses differ markedly.  
!  For successfully individualized treatment, a multitude of antipsychotic options 
are needed. 
Naber D, Lambert M.The CATIE and CUtLASS studies in schizophrenia: results and implications for 
clinicians. 
 CNS Drugs. 2009 Aug 1;23(8):649-59. 
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Lessons to take home from CATIE. 
!  Rather than selecting drugs on the basis of unfounded expectations of 
superior efficacy, clinicians can focus on selecting drugs and optimizing 
dosages to minimize adverse effects without sacrificing efficacy.  
!  Tardive dyskinesia may be a good reason to avoid a high dosage of first-
generation antipsychotics,  
!  although the evidence for differential risk is less compelling for a modest 
dosage of low-affinity first-generation antipsychotics.  
!  Similarly, the metabolic effects of some second-generation antipsychotics can 
be decisive in considering risks.  
!  In either case, the clinician should detect earliest signs and take action while 
dyskinetic or metabolic effects are most reversible. 
Carpenter WT, Buchanan RW. Lessons to take home from CATIE. Psychiatr Serv. 
2008 May;59(5):523-5. 
Bottom line: the dichotomy between first- and 
second-generation antipsychotics was not 
supported by efficacy data (and now, is not 
supported effectiveness data). 
Only clozapine has documented superiority in 
treatment-resistant cases. 
Lessons to take home from CATIE. 
Carpenter WT, Buchanan RW. Lessons to take home 
from CATIE. Psychiatr Serv. 2008 May;59(5):523-5. 
9 
Amresh Srivastava1, Nilesh Shah2, Megan 
Johnston3, Larry Stitt4, 
Meghana Thakar5, Gurusamy Chinnasamy6, 
& Anukant Mital7 
INTRODUCTION 
•  Antipsychotic medications form the mainstream of 
treatment in schizophrenia  
•  These drugs have several short term as well long term 
advantages 
•  It is not known if atypical antipsychotics have the long-
term effect of improving outcome and meeting 
expectations (1,2,3)  
10 
The present study examined the usage 
of antipsychotics drugs and their 
associations with clinical outcome in a 
long-term naturalistic study 
METHODS AND MATERIALS 
!  • First episode hospitalized schizophrenia  patients (diagnosed 
according to DSM-IIIR criteria) were followed for ten years  
!  • After ten years, diagnosis was re-confirmed (using DSM-IV 
criteria) and outcome was assessed 
!  • Outcome was assessed using Clinical Global Impression Scale 
(CGIS) 
!  • CGIS scores were correlated with key antipsychotic drugs used 
in the preceding 12 months 
11 
Multiple outcome criteria in 
schizophrenia 
Thirteen criteria 
!  Psychopathology (positive symptoms, negative 
symptoms and disorganisation) 
!  Cognitive function (attention, executive function, 
working memory, recall memory, semantic memory, 
storage memory) 
!  Interpersonal social function 
!  Work–school function  
!  Extrapyramidal function (parkinsonism, akathisia, 
tardive dyskinesia) 
Meltzer HY. Eur Psychiatry 1995;10(Suppl. 1):19S–25S 
Multiple outcome criteria in 
schizophrenia (cont’d) 
!  Independent living 
!  Aggression 
!  Quality of life 
!  Compliance 
!  Hospitalisation 
!  Family burden 
!  Social burden 
!  Suicidality 
Meltzer HY. Eur Psychiatry 1995;10(Suppl. 1):19S–25S 
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Re-assessed outcome at 10 years 
Global Social outcome 
13 
RESULTS 
! Only 62.6% improved significantly in a cohort of 
101 patients after ten years  
! 85% patients were maintained on atypical 
antipsychotics  
14 
Percentage usage pattern and per day mean dosage 
in mg at end point:  
Cognition 
!  Significant decrease in visuo-spatial function. 
!    (p=.002, Paired t), 
!  % of patients with abnormal value on BG increased but 
not significantly (p=.114, McNemar’s Chi-square test) 
!  Memory  decreased (WMS)  significantly (p=.003, Paired 
t) 
!  % of patient with abnormal values increased but not 
significantly (p=.144, McNemar’s Chi-square test) 
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Correlation between BG & WMS (Cognition) at 
Baseline and other Baseline Variables 
Correlation between BG & WMS (Cognition) at Baseline and other Baseline Variables 
BG WMS 
r P r P 
PANSS -0.210 .104 0.204 .115 
NS 0.070 .593 -0.164 .206 
PS -0.006 .966 -0.150 .249 
Duration -0.051 .695 0.350 .006 
Age at Intake -0.014 .918 -0.088 .504 
Sex .243 .059 -0.047 .717 
Association between Baseline Cognition (BG/WMS) 
and outcome parameters at 10 Year Outcomes 
Association between Baseline Cognition (GB/WMS) at baseline and 10 Year Outcomes 
BG WMS 
10 Year 
Outcomes 
Parameter 
Estimate 
(se) 
P value Parameter 
Estimate 
(se) 
P value 
PS -0.042 (0.037) .260 0.012 (0.039) .766 
NS -0.052 (0.072) .474 -0.029 (0.076) .699 
GP 0.133 (0.122) .279 0.087 (0.129) .503 
HDRS 0.071 (0.054) .196 -0.079 (0.054) .146 
GAF 0.176 (0.117) .137 0.045 (0.124) .721 
QOL -0.203 (0.109) .067 0.112 (0.116) .340 
CGIS-I 0.0005 (0.0048) .913 0.004 (0.005) .487 
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Conclusion 
Long-term Outcome of first episode 
schizophrenia does NOT  differ across 
atypical antipsychotics 
What decides quality of life of patients with 
schizophrenia? 
QO
L 
Nature of 
illness & 
Duration Quality of 
treatment & 
Accessibilit
y 
Mental 
Health 
Facilities 
Level of 
Disability 
Psychosoci
al support 
Psychosoci
al 
intervention 
EE & 
family 
Support 
Side 
effects : 
TD, 
Weight 
Comorbid 
physical 
illness 
Comorbid  
Substanc
e abuse 
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Weiden et al. Psych Services, 2004 
Cognitive 
dysfunction 
Loss Of 
Insight 
Poor 
awareness 
Drug 
Discontinuation 
Relapse 
Poor Social 
Functioning 
and 
Integration 
Pathway for poor Outcome 
Determinants of outcome in schizophrenia 
Outcome 
Patient   
Illness 
Nature of 
Treatment   
Setting of 
treatment 
Family  
environment 
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Illness Related 
–  illness loses its intensity [Dube K.C] 
–  definitions did not reveal significant variability [, Kulhara.P] 
–  Short duration of illness [vergese.et al] 
–   longer time spent in psychosis [Thara R] 
–  short-term course [Varma V.K.] 
–  Sexual, religious and grandiose delusions and flat affect [Thara, R] 
–  DUP,   [Tirupati,, Yanos PT] 
–  Relapse  [Yanos PT] 
–  Comorbidity  
–  negative syndrome   
–   cognitive functioning [Altamura AC] 
–  Premorbid level of functioning 
–  violence,  
–  severity of illness [Wittorf A] 
Patient related 
–  absence of economic difficulties,  Verghese A 
–   increase in religious activities  Verghese A 
–  a non-schizoid pre-morbid personality [Verghese A] 
–  Male [ DubeK.C.] 
19 
Family related 
–  Positive attitudes of relatives and neighbours, 
[Verghese A] 
–  EE 
–  Psycho-education [ Kulhara P.] 
Treatment related ( nature) 
–  consistent compliance 
–  Reduced levels of membrane essential 
polyunsaturated fatty acids (EPUFAs),[ Arvindakshan 
M, 
–  Rehabilitation  [Chatterjee S] 
–   limited efficacy for specific domains of 
psychopathology of current treatments; [Yanos PT] 
20 
Treatment settings 
–  Developing country , [Dube.K.C., Varma.V.K. 
Dragomirecká E, Patel V, Kulhara.P 
–  Rural background, (Verghese A] 
Environment related 
–  Mean environmental temperature [Gupta,S 
–  Bias  [Thirthalli J] 
–  Transcultural factors  [Kulhara.P] 
21 
Measures to maximise the outcome 
!  Early psychosis programme 
!  Cognitive enhancement and preservation 
!  Improvising insight, awareness and compliance 
!  Minimising EPS 
!  Minimising drop-outs and discontinuation 
!  Psycho-education 
!  Psychosocial intervention 
!  Cognitive behavioural 
!  Minimising hospital stay 
!  Relapse prevention 
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